PriceTargets.com logo

NASDAQ:NXTC - NextCure Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $23.33
  • Forecasted Upside: 77.85 %
  • Number of Analysts: 8
  • Breakdown:
  • 1 Sell Ratings
  • 4 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$13.12 As of 01/26/2021 01:00 AM ET
▼ -0.5 (-3.67%)
1 month | 3 months | 12 months
Get New NextCure Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NXTC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NXTC

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$23.33
▲ +77.85% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for NextCure in the last 3 months. The average price target is $23.33, with a high forecast of $55.00 and a low forecast of $10.00. The average price target represents a 77.85% upside from the last price of $13.12.
Hold
The current consensus among 8 contributing investment analysts is to hold stock in NextCure. This rating has held steady since July 2019, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
8/5/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
11/3/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
2/1/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
5/1/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
7/30/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
10/28/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
12/27/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
1/26/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 1 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/15/2021Bank of AmericaDowngradeNeutral ➝ Underperform$13.00 ➝ $10.00High
i
8/7/2020Needham & Company LLCReiterated RatingBuy$30.00High
i
Rating by Chad Messer at Needham & Company LLC
7/16/2020BenchmarkUpgradeHold ➝ Buy$17.00Medium
i
7/14/2020BTIG ResearchLower Price TargetBuy$61.00 ➝ $27.00High
i
7/13/2020Needham & Company LLCReiterated RatingBuy$30.00High
i
Rating by Chad Messer at Needham & Company LLC
7/13/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$11.00High
i
7/13/2020JMP SecuritiesDowngradeOutperform ➝ Market PerformHigh
i
Rating by Reni Benjamin at JMP Securities
7/13/2020Piper SandlerLower Price Target$87.00 ➝ $32.00High
i
7/13/2020Roth CapitalDowngradeBuy ➝ Neutral$15.00High
i
Rating by T. Butler at Roth Capital
7/13/2020SunTrust BanksDowngradeBuy ➝ Hold$78.00 ➝ $13.00High
i
6/1/2020BenchmarkDowngradeBuy ➝ HoldLow
i
6/1/2020Bank of AmericaDowngradeBuy ➝ Neutral$62.00 ➝ $40.00Low
i
5/26/2020JMP SecuritiesInitiated CoverageOutperform$55.00High
i
5/8/2020Needham & Company LLCReiterated RatingBuy$72.00Low
i
Rating by Chad Messer at Needham & Company LLC
5/8/2020Morgan StanleyLower Price TargetOverweight$58.00 ➝ $54.00Medium
i
4/15/2020Morgan StanleyBoost Price TargetOverweight$55.00 ➝ $58.00Medium
i
3/24/2020BenchmarkInitiated CoverageBuy$55.00High
i
3/13/2020Needham & Company LLCReiterated RatingBuy$72.00High
i
Rating by Chad Messer at Needham & Company LLC
3/2/2020Roth CapitalInitiated CoverageBuy$80.00High
i
Rating by T. Butler at Roth Capital
1/13/2020SunTrust BanksInitiated CoverageBuy$78.00High
i
12/17/2019Morgan StanleyBoost Price TargetOverweight$52.00 ➝ $55.00High
i
12/5/2019Needham & Company LLCInitiated CoverageBuy$72.00High
i
11/26/2019BTIG ResearchInitiated CoverageBuy$61.00Low
i
11/20/2019Piper Jaffray CompaniesReiterated RatingBuy$95.00 ➝ $87.00Low
i
Rating by Edward Tenthoff at Piper Jaffray Companies
11/13/2019Morgan StanleyBoost Price TargetOverweight$33.00 ➝ $52.00High
i
11/11/2019Piper Jaffray CompaniesReiterated RatingOverweight ➝ Positive$54.00 ➝ $95.00High
i
Rating by Edward Tenthoff at Piper Jaffray Companies
9/9/2019Bank of AmericaBoost Price TargetBuy$27.00 ➝ $44.00Medium
i
9/5/2019Piper Jaffray CompaniesBoost Price TargetOverweight$26.00 ➝ $54.00High
i
8/13/2019Morgan StanleyBoost Price TargetOverweight$25.00 ➝ $33.00High
i
7/9/2019Bank of AmericaInitiated CoverageBuy ➝ Buy$25.00High
i
6/3/2019Morgan StanleyInitiated CoverageOverweight ➝ Overweight$25.00High
i
6/3/2019Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$26.00High
i
(Data available from 1/27/2016 forward)
NextCure logo
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase 2 clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the B7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. NextCure, Inc. has a license agreement with Yale University; and a research and development collaboration with Eli Lilly and Company. The company was founded in 2015 and is headquartered in Beltsville, Maryland.
Read More

Today's Range

Now: $13.12
$12.91
$13.95

50 Day Range

MA: $11.59
$10.36
$13.62

52 Week Range

Now: $13.12
$7.91
$50.76

Volume

206,621 shs

Average Volume

326,396 shs

Market Capitalization

$361.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of NextCure?

The following Wall Street research analysts have issued reports on NextCure in the last twelve months: Bank of America Co., Benchmark Co., BTIG Research, JMP Securities, Morgan Stanley, Needham & Company LLC, Piper Sandler, Roth Capital, SunTrust Banks, Inc., and Zacks Investment Research.

What is the current price target for NextCure?

9 Wall Street analysts have set twelve-month price targets for NextCure in the last year. Their average twelve-month price target is $23.33, suggesting a possible upside of 77.8%. JMP Securities has the highest price target set, predicting NXTC will reach $55.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $10.00 for NextCure in the next year.

What is the current consensus analyst rating for NextCure?

NextCure currently has 1 sell rating, 4 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NXTC, but not buy more shares or sell existing shares.

What other companies compete with NextCure?

Other companies that are similar to NextCure include Cytokinetics, Ocular Therapeutix, DiaMedica Therapeutics, Travere Therapeutics, Keros Therapeutics, Mersana Therapeutics, Kiniksa Pharmaceuticals, Applied Molecular Transport, Repare Therapeutics, Athenex, Trillium Therapeutics, Innoviva, Frequency Therapeutics, BioXcel Therapeutics and MacroGenics.

How do I contact NextCure's investor relations team?

NextCure's physical mailing address is 9000 VIRGINIA MANOR ROAD SUITE 200, BELTSVILLE MD, 20705. The company's listed phone number is 240-399-4900 and its investor relations email address is [email protected] The official website for NextCure is www.nextcure.com.